Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy

Eur J Surg Oncol. 2015 Jan;41(1):94-9. doi: 10.1016/j.ejso.2014.09.001. Epub 2014 Sep 9.

Abstract

Background: The impact of neoadjuvant chemotherapy (NACT) on immediate free flap breast reconstruction remains controversial. Furthermore, the oncological outcomes of immediate free flap breast reconstruction after skin-sparing mastectomy (SSM) following NACT remain unclear. This study aimed to investigate the surgical complications and oncological outcomes of immediate perforator flap reconstruction after SSM following NACT.

Methods: A total of 201 consecutive patients with indications for immediate perforator flap reconstruction after SSM were included between 2004 and 2012. Surgical and oncological outcomes were compared between patients with and without NACT.

Results: There were 38 patients in the NACT group and 163 in the non-NACT control group. The median age of the NACT group was 39.5 years, which was significantly younger than the control group (43.0 years; P < 0.05). Patients in the NACT group also had more advanced and aggressive disease (P < 0.05). There was no significant difference in the frequency of surgical complications between the groups, no difference in the type of complications, and no significant difference in the frequencies of major and minor complications. No patients in the NACT group had delayed adjuvant therapy. Eight patients (4%) developed recurrences, with a median follow-up time of 3.0 years. Local recurrences occurred in three control patients but no patients in the NACT group.

Conclusion: NACT does not affect short-term or interim outcomes after immediate perforator flap reconstruction and may thus represent a safe and practical treatment option for the multidisciplinary treatment of breast cancer.

Keywords: Breast cancer; Immediate reconstruction; Neoadjuvant chemotherapy; Perforator flap.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / surgery*
  • Carboplatin / therapeutic use
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / surgery*
  • Carcinoma, Intraductal, Noninfiltrating / surgery*
  • Carcinoma, Lobular / surgery*
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Cyclophosphamide / therapeutic use
  • Docetaxel
  • Epirubicin / therapeutic use
  • Etoposide / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Mammaplasty / methods*
  • Mastectomy, Subcutaneous / methods*
  • Middle Aged
  • Neoadjuvant Therapy*
  • Paclitaxel / administration & dosage
  • Perforator Flap*
  • Retrospective Studies
  • Taxoids / administration & dosage
  • Trastuzumab
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • Docetaxel
  • Epirubicin
  • Etoposide
  • Cyclophosphamide
  • Carboplatin
  • Trastuzumab
  • Paclitaxel
  • Fluorouracil

Supplementary concepts

  • FEC protocol
  • JET protocol